Barrington Research Reaffirms Merit Medical Systems' Positive Outlook, Keeps Price Target at $103.00

Barrington Research maintains an "Outperform" rating for Merit Medical Systems (MMSI) with a $103 price target. Analyst Michael Petusky is confident in the company's performance, signaling stable expectations. The average one-year target price is $108.30, indicating a 30.54% upside from the current price. The average brokerage recommendation is 1.7, also indicating "Outperform" status.

Merit Medical Systems, Inc. (NASDAQ: MMSI) experienced a significant drop in its stock price, reaching a new 52-week low of $82.40 on July 30, 2025. The company's stock traded as low as $82.40 and last traded at $82.85, with a volume of 86,002 shares changing hands [1].

The stock's recent decline coincides with increased selling pressure, including significant stock sales by CFO Raul Jr. Parra and CEO Fred P. Lampropoulos. These sales, totaling 85,596 shares worth $8,171,433 in the last 90 days, suggest a potential lack of confidence among executives [1].

Analysts have provided mixed signals regarding MMSI's stock. Wells Fargo & Company and Canaccord Genuity Group maintain "overweight" ratings, while Piper Sandler and Needham & Company have lowered their price targets. Barrington Research, however, maintains an "outperform" rating with a $103 price target [1]. The average one-year target price is $108.30, indicating a 30.54% upside from the current price [2].

Institutional investors and hedge funds have also shown interest in MMSI. American Century Companies Inc., LPL Financial LLC, and Norges Bank increased their holdings in the fourth quarter [1]. However, the company's debt-to-equity ratio of 0.51 and strong financial ratios, including a quick ratio of 3.26 and a current ratio of 4.87, suggest a stable financial position [1].

Despite the mixed analyst signals and recent stock sales by executives, MMSI's strong fundamentals and growth prospects in the medical devices sector may present an attractive investment opportunity. Investors should closely monitor the company's performance and analyst ratings before making any investment decisions.

References:
[1] https://www.marketbeat.com/instant-alerts/merit-medical-systems-nasdaqmmsi-reaches-new-1-year-low-should-you-sell-2025-07-30/
[2] https://www.gurufocus.com/news/3022702/piper-sandler-lowers-price-target-for-merit-medical-systems-mmsi-to-105-mmsi-stock-news